| Gene symbol | GPRC5D | Synonyms | None | Type of gene | protein-coding |
| Chromosome | 12 | Map location | 12p13.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | G protein-coupled receptor class C group 5 member D | ||||
| GTO ID | GTC3764 |
| Trial ID | NCT06271252 |
| Disease | Multiple Myeloma |
| Altered gene | GPRC5D |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | OriCAR-017 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | A Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Anti-GPRC5D CAR-T Cell Product (OriCAR-017) in Subjects With Relapsed/Refractory Multiple Myeloma. |
| Year | 2024 |
| Country | United States |
| Company sponsor | OriCell Therapeutics Co., Ltd. |
| Other ID(s) | OriCAR-017 US-P1 |
| Cohort 1 | |||||||
|
|||||||